Liver Cancer
First patient accepted in phase III liver cancer study
Published in Hepatitis Weekly, April 5th, 2004
The patient will be treated at the Sydney melanoma unit at the Royal Price Alfred Hospital in Sydney, Australia, the initial clinical site for the company's pivotal trial.
"This is an important milestone for our company and marks the beginning of our final step toward FDA [U.S. Food and Drug Administration] approval," said M.S. Koly, CEO of Delcath. "Now that the first patient is enrolled, the clinical team in Sydney indicated to us that future enrollments should happen at a more rapid pace."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-04-05)
More Articles from Hepatitis Weekly
- Gastroenterology
Pioglitazone prevents hepatic steatosis in animal models - Infection Control
A critical juncture for hemodialysis-related HCV passage is saline flushing - Chronic Hepatitis C
The ribavirin prodrug viramidine has proven safe in healthy volunteers - Diagnostics
Non-radioactive labeled hepatitis B virus probes are sensitive and inexpensive - Gastroenterology
Microarray distinguishes the molecular signatures of hepatocellular carcinomas - Viral Genomics
Hepatitis delta virus probably harbors at least seven major clades - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
